DR. DAVID H. KATZ, M.D.
Osteopathic Medicine at La Jolla Rancho Rd, La Jolla, CA

6270746, Aug 7, 2001

Feb 17, 1999

9/251175

David H. Katz - La Jolla CA

A61K 3939, A61K 4900, G01N 3353, G01N 33563

424 92

The invention provides an IgE and antigen-specific screening assay for use in identifying agents which suppress the IgE mediated immune response to antigen. The assay is performed in vivo in animals which hyper respond to antigen by producing exaggerated levels of IgE. The animals are sensitized to an antigen during a specific window of sensitivity which closes a day after the animal has been treated to produce the IgE hyper responsive phenotype. The screening assay is performed in the animals by treating them with a candidate IgE suppressor agent in conjunction with further immunization made after closure of the window of sensitivity defined by the invention. Positive results (indicating that the candidate agent has IgE suppressive activity) are obtained in the assay through measurement of a decline in antigen-specific IgE in the animal following its treatment with the candidate agent. The screening assay may also be utilized to measure other components of the immune response to antigen, including IgG. sub. 1 and IgG. sub. 2a antibody production.

4943522, Jul 24, 1990

Aug 10, 1988

7/230642

Robert W. Eisinger - San Diego CA
Mohammed H. Khalil - San Diego CA
David H. Katz - La Jolla CA
Robert B. Sargeant - Ramona CA

Quidel - San Diego CA

G01N 3353

435 7

A method and apparatus for conducting specific binding pair assays, such as immunoassays, is described. A porous membrane capable of non-bibulous lateral flow is used as assay substrate; a member of the binding pair is affixed in an indicator zone defined in the substrate. The sample is applied at a position distant from the indicator zone and permitted to flow laterally through the zone; any analyte in the sample is complexed by the affixed specific binding member, and detected. A novel method of detection employs entrapment of observable particle in the complex. Blood is a particularly preferred sample as the red blood cells can be used as the observable particles for detection of the complex.

4253996, Mar 3, 1981

Feb 13, 1980

6/120988

David H. Katz - La Jolla CA

Scripps Clinic and Research Foundation - La Jolla CA

A61K 3702, A61K 3726, C08L 7704, C08L 8900

260 6

Techniques for preparing stable conjugates of protein-D-GL which can then be isolated in pure form are disclosed, using hen egg ovalbumin (OVA) as a prototype protein, and conjugation and purification methods are described which involve (1) application of a coupling method employing m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) as the coupling reagent, and (2) introduction of biotin moieties into D-GL molecules to allow application of avidinbiotin system for affinity chromatographic purification of conjugates. These methods are applicable to the preparation of D-GL conjugates of insulin and Ragweed Antigen E and are of general applicability.

4220565, Sep 2, 1980

Jan 18, 1979

6/004333

David H. Katz - La Jolla CA

Scripps Clinic & Research Foundation - La Jolla CA

C08L 7704, C08L 8900

260 6

Techniques for preparing stable conjugates of protein-D-GL which can then be isolated in pure form are disclosed, using hen egg ovalbumin (OVA) as a prototype protein, and conjugation and purification methods are described which involve (1) application of a coupling method employing m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) as the coupling reagent, and (2) introduction of biotin moieties into D-GL molecules to allow application of avidinbiotin system for affinity chromatographic purification of conjugates. These methods are applicable to the preparation of D-GL conjugates of insulin and Ragweed Antigen E and are of general applicability.

4388441, Jun 14, 1983

Aug 28, 1978

5/937574

David H. Katz - La Jolla CA

Scripps Clinic & Research Foundation - La Jolla CA

C08G 6948, C08G 6950

525 541

Immunosuppressive agents which are conjugates of an antigen linked to a D glutamic acid:D-lysine copolymer are disclosed. Also disclosed are methods of preparing the conjugates and therapeutic methods for inducing immunological tolerance to antigens.

5071879, Dec 10, 1991

Nov 2, 1989

7/431304

David H. Katz - La Jolla CA

Lidak Pharmaceuticals - La Jolla CA

A61K 31045

514724

Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 20 to 26, preferably 22 to 26, carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrane introduction into humans and other animals is disclosed.

5017648, May 21, 1991

Aug 10, 1990

7/565965

David H. Katz - La Jolla CA

La Jolla Pharmaceutical Company - San Diego CA

A61K 3900, A61K 3766, A61K 4300

525 541

Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.

5070107, Dec 3, 1991

Nov 2, 1989

7/430822

David H. Katz - La Jolla CA

Lidak Pharmaceuticals - La Jolla CA

A01N 3100, A61K 31045, A01J 2100

514724

Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 27 to 32 carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrance introduction into humans and other mammals is disclosed.

4874794, Oct 17, 1989

Apr 28, 1989

7/345084

David H. Katz - La Jolla CA

Lidak Biopharmaceuticals - La Jolla CA

A61V 31045

514724

A method treating virus-induced and inflammatory diseases of skin and membranes in humans or animals, comprising application of a composition consisting of one or more of the aliphatic alcohols docosanol, tetracosanol and hexacosanol in a physiologically compatible carrier is disclosed.